Recruiting
Systemic scleroderma+2
RecruitingStudy on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis
Registered drugNo placebo
Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis
Registered drugNo placebo
- Disease:Systemic sclerodermaSystemic lupus erythematosus+1
- Substances:AldesleukinCNTY-101
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Aldesleukin
